News & Updates

Back to All News

Neuroblastoma Therapeutic Strategy Unveiled By Lankenau Institute for Medical Research

November 15, 2016 In the News

A new therapeutic approach to blocking the development and progression of the childhood cancer neuroblastoma has been proposed by Susan Gilmour, PhD, Professor at Main Line Health’s Lankenau Institute for Medical Research (LIMR), and her colleagues in a multi-institutional study that was led by Michael Hogarty, MD, of The Children’s Hospital of Philadelphia (CHOP).

The researchers, whose study was published in a recent edition of the journal Clinical Cancer Research, found that therapies that disrupt polyamines (ubiquitous, small molecules that are essential for all cell growth and proliferation) stopped neuroblastoma development and progression in preclinical studies. Learn more from BioSpace.